Encelto is the first FDA-approved treatment for macular telangiectasia type 2. The cell therapy slows the loss of macular photoreceptors through continuous delivery of ciliary neurotrophic factor.
当前正在显示可能无法访问的结果。
隐藏无法访问的结果当前正在显示可能无法访问的结果。
隐藏无法访问的结果